Upregulation of sphingosine kinase 1 is associated with recurrence and poor prognosis in papillary thyroid carcinoma

Li,Jie; Zhang,Bo; Bai,Yang; Liu,Yonghong; Zhang,Buyong; Jin,Jian

doi:10.3892/ol.2019.10910

Upregulation of sphingosine kinase 1 is associated with recurrence and poor prognosis in papillary thyroid carcinoma

Authors:
- Jie Li
- Bo Zhang
- Yang Bai
- Yonghong Liu
- Buyong Zhang
- Jian Jin
View Affiliations

Affiliations: The Fourth Department of Thyroid and Breast Surgery, Cangzhou Central Hospital, Cangzhou, Hebei 061000, P.R. China
Published online on: September 24, 2019 https://doi.org/10.3892/ol.2019.10910
Pages: 5374-5382
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sphingosine kinase 1 (SPHK1), an ATP‑dependent protein, has previously been demonstrated to be upregulated in several types of human cancer and to play an important role in tumor development and progression. However, the role of SPHK1 in predicting long‑term prognosis in patients with papillary thyroid carcinoma (PTC) remains unclear. The purpose of the present study was to assess the significance of SPHK1 expression and its associations with clinicopathological characteristics and prognostic outcome in patients with PTC. Immunohistochemistry staining was retrospectively performed to investigate the expression levels of SPHK1 in 92 PTC tumors. Statistical analyses revealed that high levels of SPHK1 expression were associated with tumor size, lymph node metastasis and the Tumor‑Node‑Metastasis stage. The disease‑free survival (DFS) time of patients that exhibited high levels of SPHK1 expression was shorter, whereas patients with lower levels of SPHK1 expression survived longer. Furthermore, multivariate analysis suggested that upregulated SPHK1 was an independent prognostic factor for predicting DFS of patients with PTC. The results of the Cell Counting Kit‑8 and invasion assays demonstrated that SPHK1 overexpression significantly enhanced the proliferation and invasion of a PTC cell line, consistent with clinical findings. The results from the present study provide evidence that elevated expression levels of SPHK1 may be involved in the development and progression of PTC, indicating that this protein may act as a potential prognostic marker for patients with this disease.

View Figures

View References

1	Al-Brahim N and Asa SL: Papillary thyroid carcinoma: An overview. Arch Pathol Lab Med. 130:1057–1062. 2006.PubMed/NCBI
2	Nikiforova MN and Nikiforov YE: Molecular genetics of thyroid cancer: Implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 8:83–95. 2008. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
4	Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE and Devesa SS: Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev. 18:784–791. 2009. View Article : Google Scholar : PubMed/NCBI
5	Wang LY and Ganly I: Nodal metastases in thyroid cancer: Prognostic implications and management. Future Oncol. 12:981–994. 2016. View Article : Google Scholar : PubMed/NCBI
6	Asimakopoulos P, Nixon IJ and Shaha AR: Differentiated and medullary thyroid cancer: Surgical management of cervical lymph nodes. Clin Oncol (R Coll Radiol). 29:283–289. 2017. View Article : Google Scholar : PubMed/NCBI
7	Grant CS: Recurrence of papillary thyroid cancer after optimized surgery. Gland Surg. 4:52–62. 2015.PubMed/NCBI
8	Giusca SE, Amalinei C, Lozneanu L, Ciobanu Apostol D, Andriescu EC, Scripcariu A, Balan R, Avadanei ER and Căruntu ID: Heterogeneous periostin expression in different histological variants of papillary thyroid carcinoma. Biomed Res Int. 2017:87013862017. View Article : Google Scholar : PubMed/NCBI
9	Spiegel S and Milstien S: Functions of the multifaceted family of sphingosine kinases and some close relatives. J Biol Chem. 282:2125–2129. 2007. View Article : Google Scholar : PubMed/NCBI
10	Spiegel S and Milstien S: Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat Rev Mol Cell Biol. 4:397–407. 2003. View Article : Google Scholar : PubMed/NCBI
11	Green JA, Suzuki K, Cho B, Willison LD, Palmer D, Allen CD, Schmidt TH, Xu Y, Proia RL, Coughlin SR and Cyster JG: The sphingosine 1-phosphate receptor S1P₂ maintains the homeostasis of germinal center B cells and promotes niche confinement. Nat Immunol. 12:672–680. 2011. View Article : Google Scholar : PubMed/NCBI
12	Malavaud B, Pchejetski D, Mazerolles C, de Paiva GR, Calvet C, Doumerc N, Pitson S, Rischmann P and Cuvillier O: Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur J Cancer. 46:3417–3424. 2010. View Article : Google Scholar : PubMed/NCBI
13	Bayerl MG, Bruggeman RD, Conroy EJ, Hengst JA, King TS, Jimenez M, Claxton DF and Yun JK: Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk Lymphoma. 49:948–954. 2008. View Article : Google Scholar : PubMed/NCBI
14	French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK and Smith CD: Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 63:5962–5969. 2003.PubMed/NCBI
15	Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ and Prior TW: Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: Roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol. 64:695–705. 2005. View Article : Google Scholar : PubMed/NCBI
16	Zhu YJ, You H, Tan JX, Li F, Qiu Z, Li HZ, Huang HY, Zheng K and Ren GS: Overexpression of sphingosine kinase 1 is predictive of poor prognosis in human breast cancer. Oncol Lett. 14:63–72. 2017. View Article : Google Scholar : PubMed/NCBI
17	Li W, Tian Z, Qin H, Li N, Zhou X, Li J, Ni B and Ruan Z: High expression of sphingosine kinase 1 is associated with poor prognosis in nasopharyngeal carcinoma. Biochem Biophys Res Commun. 460:341–347. 2015. View Article : Google Scholar : PubMed/NCBI
18	Tran B, Roshan D, Abraham E, Wang L, Garibotto N, Wykes J, Campbell P and Ebrahimi A: An analysis of the American Joint Committee on Cancer 8th edition T staging system for papillary thyroid carcinoma. J Clin Endocrinol Metab. 103:2199–2206. 2018. View Article : Google Scholar : PubMed/NCBI
19	Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Schlumberger M, Sawka AM, et al: 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
20	Chen L, Zhang W, Yan W, Han L, Zhang K, Shi Z, Zhang J, Wang Y, Li Y, Yu S, et al: The putative tumor suppressor miR-524-5p directly targets Jagged-1 and Hes-1 in glioma. Carcinogenesis. 33:2276–2282. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wang HG, Cao B, Zhang LX, Song N, Li H, Zhao WZ, Li YS, Ma SM and Yin DJ: KLF2 inhibits cell growth via regulating HIF-1a/Notch-1 signal pathway in human colorectal cancer HCT116 cells. Oncol Rep. 38:584–590. 2017. View Article : Google Scholar : PubMed/NCBI
22	Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A and Plodkowski RA: Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits. 8:30–40. 2015.PubMed/NCBI
23	Popadich A, Levin O, Lee JC, Smooke-Praw S, Ro K, Fazel M, Arora A, Tolley NS, Palazzo F, Learoyd DL, et al: A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery. 150:1048–1057. 2011. View Article : Google Scholar : PubMed/NCBI
24	Hartl DM, Mamelle E, Borget I, Leboulleux S, Mirghani H and Schlumberger M: Influence of prophylactic neck dissection on rate of retreatment for papillary thyroid carcinoma. World J Surg. 37:1951–1958. 2013. View Article : Google Scholar : PubMed/NCBI
25	Bae GE, DO SI, Kim K, Park JH, Cho S and Kim HS: Increased sphingosine kinase 1 expression predicts distant metastasis and poor outcome in patients with colorectal cancer. Anticancer Res. 39:663–670. 2019. View Article : Google Scholar : PubMed/NCBI
26	Bouquerel P, Gstalder C, Müller D, Laurent J, Brizuela L, Sabbadini RA, Malavaud B, Pyronnet S, Martineau Y, Ader I and Cuvillier O: Essential role for SphK1/S1P signaling to regulate hypoxia-inducible factor 2a expression and activity in cancer. Oncogenesis. 5:e2092016. View Article : Google Scholar : PubMed/NCBI
27	Bao M, Chen Z, Xu Y, Zhao Y, Zha R, Huang S, Liu L, Chen T, Li J, Tu H and He X: Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma. Liver Int. 32:331–338. 2012. View Article : Google Scholar : PubMed/NCBI
28	Pan J, Tao YF, Zhou Z, Cao BR, Wu SY, Zhang YL, Hu SY, Zhao WL, Wang J, Lou GL, et al: An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma. J Transl Med. 9:1572011. View Article : Google Scholar : PubMed/NCBI
29	Zhang K, Chen H, Wu G, Chen K and Yang H: High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis. Med Oncol. 31:2472014. View Article : Google Scholar : PubMed/NCBI
30	Xia P, Wang L, Moretti PA, Albanese N, Chai F, Pitson SM, D'Andrea RJ, Gamble JR and Vadas MA: Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. J Biol Chem. 277:7996–8003. 2002. View Article : Google Scholar : PubMed/NCBI
31	Wattenberg BW, Pitson SM and Raben DM: The sphingosine and diacylglycerol kinase superfamily of signaling kinases: Localization as a key to signaling function. J Lipid Res. 47:1128–1139. 2006. View Article : Google Scholar : PubMed/NCBI
32	Pitson SM, Xia P, Leclercq TM, Moretti PA, Zebol JR, Lynn HE, Wattenberg BW and Vadas MA: Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med. 201:49–54. 2005. View Article : Google Scholar : PubMed/NCBI
33	Ogretmen B: Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer. 18:33–50. 2018. View Article : Google Scholar : PubMed/NCBI
34	Nema R, Vishwakarma S, Agarwal R, Panday RK and Kumar A: Emerging role of sphingosine-1-phosphate signaling in head and neck squamous cell carcinoma. Onco Targets Ther. 9:3269–3280. 2016.PubMed/NCBI
35	Pyne S and Pyne NJ: Sphingosine 1-phosphate signalling in mammalian cells. Biochem J. 349:385–402. 2000. View Article : Google Scholar : PubMed/NCBI
36	Safadi-Chamberlain F, Wang LP, Payne SG, Lim CU, Stratford S, Chavez JA, Fox MH, Spiegel S and Summers SA: Effect of a membrane-targeted sphingosine kinase 1 on cell proliferation and survival. Biochem J. 388:827–834. 2005. View Article : Google Scholar : PubMed/NCBI
37	Li W, Yu CP, Xia JT, Zhang L, Weng GX, Zheng HQ, Kong QL, Hu LJ, Zeng MS, Zeng YX, et al: Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 15:1393–1399. 2009. View Article : Google Scholar : PubMed/NCBI
38	Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, Yuan J, Zheng YJ, Huang ZS and Li M: Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res. 14:6996–7003. 2008. View Article : Google Scholar : PubMed/NCBI
39	Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio S, et al: Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res. 19:138–147. 2013. View Article : Google Scholar : PubMed/NCBI
40	Wang F and Wu Z: Sphingosine kinase 1 overexpression is associated with poor prognosis and oxaliplatin resistance in hepatocellular carcinoma. Exp Ther Med. 15:5371–5376. 2018.PubMed/NCBI
41	Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B and Cuvillier O: First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: Implication for resistance to therapeutics in prostate cancer. Mol Cancer Ther. 11:1841–1851. 2012. View Article : Google Scholar : PubMed/NCBI